Four of our panelists discuss their favorite investments in the final installment of our 2025 stock-picking confab.

BD and Biosero collaborate to integrate robotic automation with flow cytometry technology, aiming to accelerate drug discovery.

Argus Research analyst David Toung maintained a Buy rating on Johnson & Johnson (JNJ – Research Report) yesterday. The company’s shares ...

The "Live Cell Imaging Market by Product, By Application, By Technology, By End-User, and By Region" report has been added to ...

Abhijeet Bhardwaj's commitment to technical excellence and innovation continues to drive successful outcomes in large-scale ...

Becton Dickinson & Co. closed 3.20% below its 52-week high of $248.42, which the company achieved on March 28th.

BD. (BDX), a global medical technology company, and Biosero, a developer of laboratory automation solutions, Thursday announced that ...

S&P 500 surges to record highs in final week of January as investors react to economic optimism, Trump's leadership, and AI ...